Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range

Predose plasma mycophenolic acid (MPA) concentrations measured with a semi‐automated enzyme‐multiplied immunoassay were related to adverse events (e.g., rejection, leukopenia, infection), drug dose, and clinical status in 147 adult and 63 pediatric liver allograft recipients receiving adjunctive immunosuppression with mycophenolate mofetil (MMF). In 12 of 13 acute rejection episodes, predose MPA levels were below the 1 mg/L cut‐off defined using receiver operating characteristic (ROC) curve analysis. The relative risk of developing infection or leukopenia increased more than 3‐fold above predose MPA levels of 3 to 4 mg/L. Plasma MPA levels correlated weakly (r2 = 0.081) with MMF dose and the dose / level relationship was variably influenced by age, the indication for MMF, concentrations of serum albumin and creatinine, and comedication with tacrolimus or cyclosporine. The median mycophenolate dose required per unit mycophenolate level was 50% lower in children than in adults. Comparable drug requirements were also decreased by renal dysfunction (by 40 and 43% in adults and children, respectively), and in patients prescribed MMF alone rather than with tacrolimus or cyclosporine. However, in patients with serum albumin less than 35g/L, MMF dose requirements were higher than in those with normal albumin levels (by 2.1‐ and 2.6‐fold in adults and children, respectively). In adults, 44.7% achieved clinically acceptable therapeutic MPA concentrations at a dose less than 1 g MMF twice daily and only 6.3% required 1.5 g twice daily as suggested by the manufacturer. The immunoassay was a rapid, reliable, and acceptably precise technique in which only 10.8% of measurements were unproductive. In conclusion, our data suggests that MPA predose level monitoring is both clinically‐ and cost‐effective and that a therapeutic range of 1 to 3.5mg/L (by immunoassay) is applicable in liver allograft recipients given adjunctive MMF. (Liver Transpl 2004;10:492–502.)

[1]  H. Adami,et al.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden , 2003, British Journal of Cancer.

[2]  M. H. Ensom,et al.  Mycophenolate Mofetil for Solid Organ Transplantation: Does the Evidence Support the Need for Clinical Pharmacokinetic Monitoring? , 2003, Therapeutic drug monitoring.

[3]  C. Gonde,et al.  Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  W. Nahas,et al.  Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation , 2003, Pediatric Nephrology.

[5]  J. Tredger,et al.  Mycophenolic Acid and Mycophenolic Acid Glucuronide Pharmacokinetics in Pediatric Liver Transplant Recipients: Effect of Cyclosporine and Tacrolimus Comedication , 2002, Therapeutic drug monitoring.

[6]  K. Eckardt,et al.  Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  D. Holt Monitoring mycophenolic acid , 2002, Annals of clinical biochemistry.

[8]  L. Weber,et al.  The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. , 2002, Journal of the American Society of Nephrology : JASN.

[9]  L. Weber,et al.  Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. , 2002, Clinical chemistry.

[10]  L. Shaw,et al.  Monitoring of Mycophenolic Acid in Clinical Transplantation , 2002, Therapeutic drug monitoring.

[11]  L. Shaw,et al.  Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion , 2001, Therapeutic drug monitoring.

[12]  J. Fung,et al.  Pharmacokinetics of Mycophenolic Acid after Mycophenolate Mofetil Administration in Liver Transplant Patients Treated with Tacrolimus , 2001 .

[13]  L. Shaw,et al.  Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. , 2001, Clinical biochemistry.

[14]  J. Squifflet,et al.  Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. , 2001, Clinical chemistry.

[15]  L. Shaw,et al.  Mycophenolic acid concentrations are associated with cardiac allograft rejection. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  C. Cantarell,et al.  Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. , 2000, Pharmacology & toxicology.

[17]  N. Smedira,et al.  The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. , 2000, Transplantation.

[18]  V. Armstrong,et al.  Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. , 2000, Clinical chemistry.

[19]  L. Weber,et al.  Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 2000, Therapeutic drug monitoring.

[20]  L. Shaw,et al.  Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. , 2000, Therapeutic drug monitoring.

[21]  G. Filler,et al.  Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression , 2000, Pediatric Nephrology.

[22]  L. Weber,et al.  Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 1999, Therapeutic drug monitoring.

[23]  D. Holt,et al.  Therapeutic drug monitoring of immunosuppressant drugs. , 1999, British journal of clinical pharmacology.

[24]  W. Weimar,et al.  Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  A. Tsaroucha,et al.  Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. , 1999, Therapeutic drug monitoring.

[26]  H. Reichenspurner,et al.  Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  L. Weber,et al.  Pharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients--a multicentre study. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  A. Nicholls Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. , 1998, Clinical biochemistry.

[29]  W. Weimar,et al.  Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. , 1998, Transplantation proceedings.

[30]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[31]  A. Trull Therapeutic Monitoring of Tacrolimus , 1998, Annals of clinical biochemistry.

[32]  J. Squifflet,et al.  A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. , 1998, Transplantation.

[33]  Mark A. Murcko,et al.  Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid , 1996, Cell.

[34]  B. Kahan The Evolution of Therapeutic Immunosuppression and the Potential Impact of Drug Concentration Monitoring , 1995, Therapeutic drug monitoring.